VMM yields 152.33% · JNJ yields 2.13%● Live data
📍 VMM pulled ahead of the other in Year 1
Combined, VMM + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VMM + JNJ for your $10,000?
Delaware Investments Minnesota Municipal Income Fund II, Inc. is a closed ended fixed income mutual fund launched by Delaware Management Holdings, Inc. The fund is managed by Delaware Management Business Trust. It invests in fixed income markets of the United States. The fund primarily invests in investment grade municipal bonds, which include airport revenue bonds, city general obligation bonds, continuing care and retirement revenue bonds, corporate backed revenue bonds, escrowed to maturity bonds, higher education revenue bonds, hospital revenue bonds, multifamily housing revenue bonds, municipal lease revenue bonds, parking revenue bonds, political subdivision general obligation bonds, pre-refunded bonds, public power revenue bonds, school district general obligation bonds, single family housing revenue bonds, state general obligation bonds, tax increment and special assessment bonds, territorial general obligation bonds, and territorial revenue bonds. It benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The fund was previously known as Voyageur Minnesota Municipal Income Fund II, Inc. Delaware Investments Minnesota Municipal Income Fund II, Inc. was formed in 1992 and is domiciled in the United States.
Full VMM Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.